Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Location Sciences Group Plc | LSAI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 134.375 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 134.375 |
| Industry Sector |
|---|
| TECHNOLOGY HARDWARE & EQUIPMENT |
| Top Posts |
|---|
Posted at 25/1/2024 07:47 by cancun tango Wow, that loan facility looks like a great deal. Unfortunately, it looks like a great deal for Bidco 3 not LSAI |
Posted at 14/1/2022 13:51 by plunge There is a lot of useful content and discussion on the Location Sciences #LSAI Telegram forum. You can always join it. |
Posted at 06/1/2022 13:44 by tima441 LSAI Target of 1.2pAlways nice if charts & fundamentals agree! |
Posted at 30/12/2021 09:00 by plunge Here is another enlightening post from Muck165 on the LSE chat forum.Always useful to look at time lines… Hughes/Kamani invest in Avacta early 2020 They shortly then set upM19, and get exclusive B2C rights, and non exclusive B2B rights to the Avacta test. M19 tried to get their own RSPT test away, but that seems to have failed, largely I think because it’s an antibody not an antigen test. Then in April it seems Hughes and Kamani lumped more cash into M19 Healthcare (see charges registered at companies house) In May they, with a concert group of family, Cheshire based investors, and notably Stephenson of M19, invest in LSAI, a business on its knees, ostensibly to drive the existing business. But shortly thereafter they give notice to the 2 remaining legacy Directors (promising to ensure they benefit from the EXISTING business), and begin to sell down assets. From June/July onwards M19 is like tumbleweed on social media..weird for sales and marketing experts. We now know that in this period their focus has been getting HUA for AffiDx, building Saturn Pass, and potentially also Agile. They trademarked Meduflow in November, but despite the HUA appear to have done next to nothing to promote it. Perhaps they don’t need to because of deals going on behind the scenes? Whatever, I’m convinced that there was zero reason for the concert party to buy into LSAI unless it was M19 linked, and the fact LSAI has £20m of prior trading losses to use may well have been a primary driver. |
Posted at 28/12/2021 21:44 by plunge We may see further upticks in the share price if punters (especially from the Avacta board) see LSAI as a potential play in tying up with Medusa 19. |
Posted at 28/12/2021 07:36 by tima441 What's the future hold? - not advice!Currently I think this is key....if my maths right...& lump Directors with Concert Party... - They currently have around 757m shs out of 2.6bil. Just under 30%. - If they exercise all warrants & options they will have around 2.7bil out of 4.6bil shs outstanding I.e. almost 60%. - 757m cost them approx £1.5m afaik - Roughly another 2bil will cost them around £4m. (most 0.2p.. some higher. Say another £4m cash into co. But will not exercise yet - as they will not want to bid What next? stressing this is just my guess: - Do a big placing at 1p (or more)... and buy @medusa19_ - Big placing at 1p... then trading at say 1.5p.... everyone happy!!!!! Potential Placing - Again stressing just a guess & idle musings: Issue 10bil shs at 1p = £100m cash Total shs out 12.6bil - Concert Party subscribe for 1.5bil new shs giving them 2.2bil in total (17.5%) but after exercise of options & warrants 4.2bil out of 12.6bil i.e. almost 30% (keeping under bid threshold) War-chest - £100m from placing - £4m from from warrants/options exercise Buy Medusa19 - Hughes & Kamani invested £20m in Dec 2020 & have built significant business including recently: AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU. - LSAI pay £50m(?) for Medusa19? - Possibly add Saturn Pass too? Other actions: - Rename LSAI as Medusa19 - Integrate Verify with SaturnPass if synergies exist? Or Divest previous business - Consolidate shares 10:1 so 1.26bil outstanding with say £50m cash - Possibly take stake(s) in one or more LFT manufacturer? (ABDX? ODX?) or better to remain ind from manufacturers? Enterprise value? 1.26 bil shs trading at say 15p = £189m mkt cap Concert Party 420m shs @ 15p = £63m Vs cost 270m @ 2p = £5.4m 150m @ 10p = £15m Total £20.4m Hughes/Kamani g I welcome feedback, comments or alternative views! |
Posted at 27/12/2021 14:49 by tima441 New poll added to Telegram group for #LSAIPlans for 2022? RTO Medusa19? Placing at premium to fund RTO? Join group via link |
Posted at 10/12/2021 15:46 by plunge From the link below, it looks like GeoProve is offering the exact same solution for validating location data that LSAI has done in the past.Now the question is, has it reinvented the wheel or has it acquired the technology from LSAI? My guess it's the latter but let us see. |
Posted at 21/11/2021 08:53 by pwhite73 If LSAI is intending to close its doors then the 6 million dump at 0.39p is clearly a sign of insider trading and a criminal offence. |
Posted at 20/11/2021 11:16 by stephenk123 Looks like frm Thr morning.... Probably someone lost patience.If Lsai was going to close its doors what would have been the point from Boohoo and Hughes!? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
